← Leaderboards
Jason Moffat
University Of Toronto
$409,677
Attributed
$1,229,031
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $268K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,229,031 · 1
By mechanism
R01$1,229,031 · 1
Top collaborators
- Stephane Angers5 shared
- Shana O Kelley5 shared
Most similar at University Of Toronto
Same institution · by research overlap
- Leah Elizabeth Cowen$8,295,527
- Chad L Myers$5,777,157
Others in their field
Other Emerging Leaders on “Crispr/Cas Technology”
- William H. Peranteau · Children'S Hosp Of Philadelphia$16,284,236
- Crystal Mackall · Children'S Hosp Of Philadelphia$13,090,386
- Jacqueline K White · Jackson Laboratory$11,881,166
- Jesse M Engreitz · Stanford University$8,776,071
- Peng Jiang · Rutgers, The State Univ Of N.J.$6,578,144
- Yin Shen · University Of California, San Francisco$6,515,212
Research focus
Crispr/Cas TechnologyDatabasesAntibodies3d PrintCrispr ScreenBiologicalCancer BiologyCancer ImmunotherapyCancer TherapyCancer TypeCd47 GeneBenchmarkingCell FixationCell LineCellsCell SeparationCell SurfaceCell Surface ProteinsCell SurvivalCell TypeCheckpoint TherapyCommunitiesCostData Set
Grant awards (5)
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$239,392
R01 · FY2025 · CA
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$249,479
R01 · FY2024 · CA
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$259,550
R01 · FY2023 · CA
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$268,031
R01 · FY2022 · CA
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$212,579
R01 · FY2021 · CA